Corcept Therapeutics (CORT) Short-term Investments (2017 - 2026)

Corcept Therapeutics has disclosed Short-term Investments across 10 years of filings, most recently posting $229.4 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $229.4 million, down 1.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $229.4 million (down 1.5% YoY), and the FY2025 annual result was $251.7 million, down 1.57% from the prior year.
• Short-term Investments came in at $229.4 million for Q1 2026 at Corcept Therapeutics, down from $251.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $365.3 million in Q4 2022 to a low of $165.1 million in Q1 2023.
• The 5-year median for Short-term Investments is $251.7 million (2025), against an average of $265.7 million.
• Across the five-year window, Short-term Investments soared 150.38% in 2022 and tumbled 42.98% in 2023, its largest moves.
• Corcept Therapeutics' Short-term Investments stood at $365.3 million in 2022, then tumbled by 36.31% to $232.7 million in 2023, then grew by 9.88% to $255.7 million in 2024, then declined by 1.57% to $251.7 million in 2025, then slipped by 8.83% to $229.4 million in 2026.
• The last three Short-term Investments figures came in at $229.4 million (Q1 2026), $251.7 million (Q4 2025), and $296.5 million (Q3 2025), per Business Quant data.